202 related articles for article (PubMed ID: 20124173)
21. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Coates AS; Winer EP; Goldhirsch A; Gelber RD; Gnant M; Piccart-Gebhart M; Thürlimann B; Senn HJ;
Ann Oncol; 2015 Aug; 26(8):1533-46. PubMed ID: 25939896
[TBL] [Abstract][Full Text] [Related]
22. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
23. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
Mehta RS
J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
[No Abstract] [Full Text] [Related]
24. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
Warm M; Kates R; Mallmann P; Dick M; Nawroth F; Harbeck N; Paepke S; Thomas A
Anticancer Res; 2007; 27(2):1031-8. PubMed ID: 17465239
[TBL] [Abstract][Full Text] [Related]
25. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
[TBL] [Abstract][Full Text] [Related]
26. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
27. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis.
Zhang N; Moran MS; Huo Q; Haffty BG; Yang Q
Cancer Invest; 2011 Nov; 29(9):594-8. PubMed ID: 22011281
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy after breast-conservation surgery: how much is enough?
Deutsch M
Semin Surg Oncol; 1992; 8(3):140-6. PubMed ID: 1496224
[TBL] [Abstract][Full Text] [Related]
29. Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience.
Santiago RJ; Harris EE; Qin L; Hwang WT; Solin LJ
Cancer; 2005 Jun; 103(12):2447-54. PubMed ID: 15887223
[TBL] [Abstract][Full Text] [Related]
30. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients.
Cutuli B; Cottu PH; Guastalla JP; Mechin H; Costa A; Jourdan R
Breast Cancer Res Treat; 2006 Jan; 95(1):55-64. PubMed ID: 16261401
[TBL] [Abstract][Full Text] [Related]
31. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for patients with liver metastases from breast cancer.
Eichbaum MH; Kaltwasser M; Bruckner T; de Rossi TM; Schneeweiss A; Sohn C
Breast Cancer Res Treat; 2006 Mar; 96(1):53-62. PubMed ID: 16319993
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy in the treatment of breast cancer.
Redden MH; Fuhrman GM
Surg Clin North Am; 2013 Apr; 93(2):493-9. PubMed ID: 23464698
[TBL] [Abstract][Full Text] [Related]
34. Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.
Cutuli B; Dalenc F; Cottu PH; Gligorov J; Guastalla JP; Petit T; Amrate A
Cancer Radiother; 2015 Aug; 19(5):295-302. PubMed ID: 26188735
[TBL] [Abstract][Full Text] [Related]
35. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
Parton M; Krajewski S; Smith I; Krajewska M; Archer C; Naito M; Ahern R; Reed J; Dowsett M
Clin Cancer Res; 2002 Jul; 8(7):2100-8. PubMed ID: 12114409
[TBL] [Abstract][Full Text] [Related]
36. Biologic tumor markers, lymph node status, and decision about adjuvant chemotherapy for breast cancer.
Velanovich V
Am Surg; 1997 Apr; 63(4):330-3. PubMed ID: 9124752
[TBL] [Abstract][Full Text] [Related]
37. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
[TBL] [Abstract][Full Text] [Related]
38. [Neoadjuvant systemic chemotherapy for patients with operable breast cancer].
Zhang B; Zhang Q
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):161-5. PubMed ID: 17649628
[No Abstract] [Full Text] [Related]
39. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
40. [Neoadjuvant chemotherapy for primary breast cancer].
Li JF; Ouyang T; Wang TF; Lin BY
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
